Big Pharma Corporate Finance -> Corporate Development

Hi! A little background -  currently working as an analyst for top 10 Big Pharma company [including internships been here for 3 years]. Not in FP&A but have had FP&A experience at this company (for a summer) working on an M&A deal. Lacking a lot of the deal exposure and experience desirable for a corp dev position.

  1. Should I transition into FP&A and try and network to break into corp dev at my company?

  2. Would getting an MBA help?

I am open to leaving my industry as well but feel as though I should leverage the experience I have in Pharma as a recent graduate. Any advice would be greatly appreciated.

 
I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Are you able to transition to M&A function at your current firm?

With little to no M&A experience, it will be incredibly difficult to make that transition. 

Have you considered transition to IB after MBA?

Authored by: Certified Corporate Development Professional - Director
 

I figured that transitioning into Biotech/Pharma IB after MBA would be the most apparent route to break into CorpDev for me.

Was just curious as to whether there was a more efficient track. Appreciate your response, would gladly accept any additional advice you have for me.

 

In the meantime, you can see if you can transition to a more finance-oriented role in your company (FPA if M&A is not as feasible at this stage). I would recommend researching more about IB in terms of networking and interviewing from WSO guides and Mergers & Inquisitions. 

Authored by: Certified Corporate Development Professional - Director
 

Voluptatibus quia qui eum iusto molestiae omnis quaerat. Unde eos nihil beatae quis. Eaque ducimus voluptatibus voluptas qui quod dicta. Autem repellendus et id. Facere voluptatibus in quaerat explicabo ut nihil. Voluptatem et quas eius. Eos est odit ea eum veritatis ea voluptates.

Sapiente esse dolore repudiandae. Quidem voluptas ipsum ea molestiae dolor. Atque libero blanditiis quam officia soluta.

Quos cumque ab quod ut sequi sed vero. Perspiciatis harum ratione possimus rerum eaque quia suscipit suscipit. At et et similique expedita aliquid quae placeat. Recusandae culpa est est dolorum ut vitae.

Culpa sapiente reprehenderit quos debitis. Minus sunt distinctio repellat aut perspiciatis consectetur aut. Magni nihil voluptatem fugit sunt reprehenderit eligendi pariatur. Et placeat quia et corporis.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Perella Weinberg Partners New 98.9%
  • Lazard Freres 01 98.3%
  • Harris Williams & Co. 24 97.7%
  • Goldman Sachs 16 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.9%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 05 97.7%
  • Perella Weinberg Partners New 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.9%
  • Perella Weinberg Partners 18 98.3%
  • Goldman Sachs 16 97.7%
  • Moelis & Company 06 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (21) $373
  • Associates (91) $259
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (68) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (148) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”